Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Induction of circulating T follicular helper cells and regulatory T cells correlating with HIV-1 gp120 variable loop antibodies by a subtype C prophylactic vaccine tested in a Phase I trial in India.

Munusamy Ponnan S, Swaminathan S, Tiruvengadam K, K K V, Cheedarla N, Nesakumar M, Kathirvel S, Goyal R, Singla N, Mukherjee J, Bergin P, T Kopycinski J, Gilmour J, Prasad Tripathy S, Luke HE.

PLoS One. 2018 Aug 29;13(8):e0203037. doi: 10.1371/journal.pone.0203037. eCollection 2018. Erratum in: PLoS One. 2018 Sep 19;13(9):e0204476.

2.

The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccination.

Hollister K, Chen Y, Wang S, Wu H, Mondal A, Clegg N, Lu S, Dent A.

Hum Vaccin Immunother. 2014;10(7):1985-92. doi: 10.4161/hv.28659.

3.

Induction and maintenance of bi-functional (IFN-γ + IL-2+ and IL-2+ TNF-α+) T cell responses by DNA prime MVA boosted subtype C prophylactic vaccine tested in a Phase I trial in India.

Munusamy Ponnan S, Pattabiram S, Thiruvengadam K, Goyal R, Singla N, Mukherjee J, Chatrath S, Bergin P, T Kopycinski J, Gilmour J, Kumar S, Muthu M, Subramaniam S, Swaminathan S, Prasad Tripathy S, Luke HE.

PLoS One. 2019 Mar 28;14(3):e0213911. doi: 10.1371/journal.pone.0213911. eCollection 2019.

4.

Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers.

Mehendale S, Thakar M, Sahay S, Kumar M, Shete A, Sathyamurthi P, Verma A, Kurle S, Shrotri A, Gilmour J, Goyal R, Dally L, Sayeed E, Zachariah D, Ackland J, Kochhar S, Cox JH, Excler JL, Kumaraswami V, Paranjape R, Ramanathan VD.

PLoS One. 2013;8(2):e55831. doi: 10.1371/journal.pone.0055831. Epub 2013 Feb 13.

5.

Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.

Townsley S, Mohamed Z, Guo W, McKenna J, Cleveland B, LaBranche C, Beaumont D, Shen X, Yates NL, Pinter A, Tomaras GD, Ferrari G, Montefiori DC, Hu SL.

J Virol. 2016 Sep 12;90(19):8644-60. doi: 10.1128/JVI.00853-16. Print 2016 Oct 1.

6.

HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.

Nilsson C, Hejdeman B, Godoy-Ramirez K, Tecleab T, Scarlatti G, Bråve A, Earl PL, Stout RR, Robb ML, Shattock RJ, Biberfeld G, Sandström E, Wahren B.

PLoS One. 2015 Jun 29;10(6):e0131748. doi: 10.1371/journal.pone.0131748. eCollection 2015.

7.

An HIV-1 envelope immunogen with W427S mutation in CD4 binding site induced more T follicular helper memory cells and reduced non-specific antibody responses.

Yu HT, Tian D, Wang JY, Guo CX, Li Y, Wang X, Li D, Zhang FM, Zhuang M, Ling H.

PLoS One. 2014 Dec 29;9(12):e115047. doi: 10.1371/journal.pone.0115047. eCollection 2014.

8.

HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.

García-Arriaza J, Perdiguero B, Heeney JL, Seaman MS, Montefiori DC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Self SG, Borate B, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Lee C, Kibler KV, Jacobs BL, Wagner R, Ding S, Pantaleo G, Esteban M.

J Virol. 2017 Apr 13;91(9). pii: e02182-16. doi: 10.1128/JVI.02182-16. Print 2017 May 1.

9.

Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.

Hayes P, Gilmour J, von Lieven A, Gill D, Clark L, Kopycinski J, Cheeseman H, Chung A, Alter G, Dally L, Zachariah D, Lombardo A, Ackland J, Sayeed E, Jackson A, Boffito M, Gazzard B, Fast PE, Cox JH, Laufer D.

Clin Vaccine Immunol. 2013 Mar;20(3):397-408. doi: 10.1128/CVI.00637-12. Epub 2013 Jan 23.

10.

A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.

Thongcharoen P, Suriyanon V, Paris RM, Khamboonruang C, de Souza MS, Ratto-Kim S, Karnasuta C, Polonis VR, Baglyos L, Habib RE, Gurunathan S, Barnett S, Brown AE, Birx DL, McNeil JG, Kim JH; Thai AIDS Vaccine Evaluation Group.

J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):48-55.

PMID:
17909315
11.

Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.

Nilsson C, Godoy-Ramirez K, Hejdeman B, Bråve A, Gudmundsdotter L, Hallengärd D, Currier JR, Wieczorek L, Hasselrot K, Earl PL, Polonis VR, Marovich MA, Robb ML, Sandström E, Wahren B, Biberfeld G.

AIDS Res Hum Retroviruses. 2014 Mar;30(3):299-311. doi: 10.1089/AID.2013.0149. Epub 2013 Nov 15.

12.

Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.

Guardo AC, Gómez CE, Díaz-Brito V, Pich J, Arnaiz JA, Perdiguero B, García-Arriaza J, González N, Sorzano COS, Jiménez L, Jiménez JL, Muñoz-Fernández MÁ, Gatell JM, Alcamí J, Esteban M, López Bernaldo de Quirós JC, García F, Plana M; RISVAC02boost study.

PLoS One. 2017 Oct 24;12(10):e0186602. doi: 10.1371/journal.pone.0186602. eCollection 2017. Erratum in: PLoS One. 2018 Apr 10;13(4):e0195915.

13.

Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.

Gray GE, Mayer KH, Elizaga ML, Bekker LG, Allen M, Morris L, Montefiori D, De Rosa SC, Sato A, Gu N, Tomaras GD, Tucker T, Barnett SW, Mkhize NN, Shen X, Downing K, Williamson C, Pensiero M, Corey L, Williamson AL.

Clin Vaccine Immunol. 2016 Jun 6;23(6):496-506. doi: 10.1128/CVI.00717-15. Print 2016 Jun.

15.

In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses.

Huang X, Zhu Q, Huang X, Yang L, Song Y, Zhu P, Zhou P.

Vaccine. 2017 Apr 11;35(16):2042-2051. doi: 10.1016/j.vaccine.2017.03.006. Epub 2017 Mar 17.

PMID:
28318765
16.

HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Gorse GJ, Corey L, Patel GB, Mandava M, Hsieh RH, Matthews TJ, Walker MC, McElrath MJ, Berman PW, Eibl MM, Belshe RB.

AIDS Res Hum Retroviruses. 1999 Jan 20;15(2):115-32.

PMID:
10029244
17.

The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.

de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P, Paris RM, Kaewkungwal J, Michael NL, Rerks-Ngarm S, Mathieson B, Marovich M, Currier JR, Kim JH; Ministry of Public Health–Thai AIDS Vaccine Evaluation Group Collaborators.

J Immunol. 2012 May 15;188(10):5166-76. doi: 10.4049/jimmunol.1102756. Epub 2012 Apr 23.

18.

Harnessing T Follicular Helper Cell Responses for HIV Vaccine Development.

Niessl J, Kaufmann DE.

Viruses. 2018 Jun 19;10(6). pii: E336. doi: 10.3390/v10060336. Review.

19.

Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers.

Rubinstein A, Goldstein H, Pettoello-Mantovani M, Mizrachi Y, Bloom BR, Furer E, Althaus B, Que JU, Hasler T, Cryz SJ.

AIDS. 1995 Mar;9(3):243-51.

PMID:
7755912
20.

Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site.

Bogers WMJM, Barnett SW, Oostermeijer H, Nieuwenhuis IG, Beenhakker N, Mortier D, Mooij P, Koopman G, Remarque E, Martin G, Lai RP, Dey AK, Sun Y, Burke B, Ferrari G, Montefiori D, Martin L, Davis D, Srivastava I, Heeney JL.

J Virol. 2017 Sep 12;91(19). pii: e00811-17. doi: 10.1128/JVI.00811-17. Print 2017 Oct 1.

Supplemental Content

Support Center